Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer

Nilsen, 2001, Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis, Br J Cancer, 84, 417, 10.1054/bjoc.2000.1582 Verlato, 2003, Mortality from site-specific malignancies in type 2 diabetic patients from verona, Diabetes Care, 26, 1047, 10.2337/diacare.26.4.1047 Richardson, 2005, Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer, Nat Clin Pract Oncol, 2, 48, 10.1038/ncponc0062 Coughlin, 2004, Diabetes mellitus as a predictor of cancer mortality in a large cohort of us adults, Am J Epidemiol, 159, 1160, 10.1093/aje/kwh161 Lipscombe, 2008, The impact of diabetes on survival following breast cancer, Breast Cancer Res Treat, 109, 389, 10.1007/s10549-007-9654-0 Yancik, 2001, Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older, JAMA, 285, 885, 10.1001/jama.285.7.885 van de Poll-Franse, 2007, Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis, Int J Cancer, 120, 1986, 10.1002/ijc.22532 Srokowski, 2009, Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer, J Clin Oncol, 27, 2170, 10.1200/JCO.2008.17.5935 Tammemagi, 2005, Comorbidity and survival disparities among black and white patients with breast cancer, JAMA, 294, 1765, 10.1001/jama.294.14.1765 Du, 2005, Racial disparities in treatment and survival of women with stage i-iii breast cancer at a large academic medical center in metropolitan Detroit, Breast Cancer Res Treat, 91, 243, 10.1007/s10549-005-0324-9 Fleming, 2005, Comorbidity as a predictor of stage of illness for patients with breast cancer, Med Care, 43, 132, 10.1097/00005650-200502000-00006 Fleming, 1999, A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer, Med Care, 37, 601, 10.1097/00005650-199906000-00009 Peairs, 2011, Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis, J Clin Oncol, 29, 40, 10.1200/JCO.2009.27.3011 Schrauder, 2011, Diabetes and prognosis in a breast cancer cohort, J Cancer Res Clin Oncol, 137, 975, 10.1007/s00432-010-0960-2 Pasanisi, 2006, Metabolic syndrome as a prognostic factor for breast cancer recurrences, Int J Cancer, 119, 236, 10.1002/ijc.21812 Benson, 2009, Early breast cancer, Lancet, 373, 1463, 10.1016/S0140-6736(09)60316-0 Giovannucci, 2010, Diabetes and cancer: a consensus report, Diabetes Care, 33, 1674, 10.2337/dc10-0666 Esteva, 2001, Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry, Pathol Oncol Res, 7, 171, 10.1007/BF03032345 Jin, 2008, Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer, J Mammary Gland Biol Neoplasia, 13, 485, 10.1007/s10911-008-9107-3 Esteva, 2002, Molecular prognostic factors for breast cancer metastasis and survival, Semin Radiat Oncol, 12, 319, 10.1053/srao.2002.35251 Brewster, 2008, Residual risk of breast cancer recurrence 5 years after adjuvant therapy, J Natl Cancer Inst, 100, 1179, 10.1093/jnci/djn233 Pollak, 2008, Insulin and insulin-like growth factor signalling in neoplasia, Nat Rev Cancer, 8, 915, 10.1038/nrc2536 Esteva, 2004, Prognostic significance of phosphorylated p38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma, Cancer, 100, 499, 10.1002/cncr.11940 Goodwin, 2002, Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study, J Clin Oncol, 20, 42, 10.1200/JCO.2002.20.1.42 Irwin, 2011, Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study, J Clin Oncol, 29, 47, 10.1200/JCO.2010.28.4752 Goodwin, 2008, Insulin-lowering effects of metformin in women with early breast cancer, Clin Breast Cancer, 8, 501, 10.3816/CBC.2008.n.060 Feng, 2011, The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth, J Cell Mol Med, 15, 825, 10.1111/j.1582-4934.2010.01083.x Alimova, 2009, Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro, Cell Cycle, 8, 909, 10.4161/cc.8.6.7933 Hirsch, 2009, Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission, Cancer Res, 69, 7507, 10.1158/0008-5472.CAN-09-2994 Zakikhani, 2006, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells, Cancer Res, 66, 10269, 10.1158/0008-5472.CAN-06-1500 Zhuang, 2008, Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1, J Mol Signal, 3, 18, 10.1186/1750-2187-3-18 Zhuang, 2011, Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells, Mol Cancer Res, 9, 603, 10.1158/1541-7786.MCR-10-0343 Dowling, 2007, Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells, Cancer Res, 67, 10804, 10.1158/0008-5472.CAN-07-2310 Elstner, 1998, Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice, Proc Natl Acad Sci U S A, 95, 8806, 10.1073/pnas.95.15.8806 Yin, 2001, Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators, Biochem Biophys Res Commun, 286, 916, 10.1006/bbrc.2001.5491 Yang, 2003, HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy, Clin Cancer Res, 9, 3198 Tikoo, 2009, Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats, BMC Cancer, 9, 107, 10.1186/1471-2407-9-107 Wang, 2009, Thiazolidinediones downregulate Wnt/beta-catenin signaling via multiple mechanisms in breast cancer cells, J Surg Res, 153, 210, 10.1016/j.jss.2008.05.032 Rashid-Kolvear, 2010, Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells, BMC Cancer, 10, 390, 10.1186/1471-2407-10-390 Friday, 2011, Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: relationship to mitochondrial membrane potential, J Cell Physiol, 226, 511, 10.1002/jcp.22360 He, 2011, Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients, Ann Oncol, 22, 2640, 10.1093/annonc/mdr020 Vazquez-Martin, 2009, The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells, Cell Cycle, 8, 88, 10.4161/cc.8.1.7499 Anisimov, 2010, Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo, Cell Cycle, 9, 188, 10.4161/cc.9.1.10407 Zheng, 2011, Association between body-mass index and risk of death in more than 1 million Asians, N Engl J Med, 364, 719, 10.1056/NEJMoa1010679 Berrington de Gonzalez, 2010, Body-mass index and mortality among 1.46 million white adults, N Engl J Med, 363, 2211, 10.1056/NEJMoa1000367 Scrucca, 2007, Competing risk analysis using R: an easy guide for clinicians, Bone Marrow Transplant, 40, 381, 10.1038/sj.bmt.1705727 Dean-Colomb, 2008, HER2-positive breast cancer: herceptin and beyond, Eur J Cancer, 44, 2806, 10.1016/j.ejca.2008.09.013 Esteva, 2010, Molecular predictors of response to trastuzumab and lapatinib in breast cancer, Nat Rev Clin Oncol, 7, 98, 10.1038/nrclinonc.2009.216 Bowker, 2006, Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin, Diabetes Care, 29, 254, 10.2337/diacare.29.02.06.dc05-1558 Li, 2009, Antidiabetic therapies affect risk of pancreatic cancer, Gastroenterology, 137, 482, 10.1053/j.gastro.2009.04.013 Renehan, 2010, Linking diabetes and cancer: a consensus on complexity, Lancet, 375, 2201, 10.1016/S0140-6736(10)60706-4 Gouveri, 2011, The female breast and diabetes, Breast, 20, 205, 10.1016/j.breast.2011.02.019